Archive for December, 2019

IRVING, Texas and ALISO VIEJO, Calif., Dec. 4, 2019 /PRNewswire/ --Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, and Ambry Genetics(Ambry), a leading clinical genetic testing company, today announced that Caris will begin offering Ambry's 67-gene CancerNext-Expanded panel to evaluate the hereditary risks for cancer. Combined with Caris' somatic (tumor) tests that analyze a cancer's detailed molecular makeup, Caris will provide patients and their healthcare providers unparalleled information to more accurately diagnose and treat cancer. This will be the most comprehensive, clinically relevant molecular and genetic offering on the market today to guide treatment and management of cancer.

"We are committed to providing clinicians with high-quality information they can use to inform treatment decisions," said David D. Halbert, Caris Life Sciences Chairman, Chief Executive Officer and Founder. "By partnering with Ambry Genetics to better inform patient care, we are able to provide clinicians a greater ability to learn about a cancer's molecular composition."

Caris currently offers clinicians Caris Molecular Intelligence, a proprietary, comprehensive tumor profiling approach that assesses DNA, RNA, and proteins unique to an individual's cancer to reveal a molecular blueprint in order to guide more precise and individualized treatment decisions.

Through the partnership, Caris will now offer Ambry's CancerNext-Expanded hereditary cancer panel. This panel analyzes 67 genes associated with an increased hereditary risk of cancer, including brain, breast, colon, ovarian, pancreatic, prostate, renal, uterine, and many other cancers. Its comprehensive testing identifies inherited risks for cancer in order for clinicians to accurately diagnose, treat, and manage cancer risks for each patient's needs.

"To best diagnose and treat cancer, clinicians must understand whether patients have mutations in genes associated with an increased risk for hereditary cancer," said Aaron Elliott, Chief Executive Officer of Ambry. "Caris' molecular tests combined with Ambry's germline genetic testing, give clinicians the most comprehensive, clinically relevant molecular profile on the market to guide treatment and management."

The combined Caris and Ambry testing is now available nationwide.

"Being able to simultaneously conduct comprehensive tumor genomic testing and multi-gene germline sequencing is invaluable, especially for sick patients at the beginning of their cancer journey," said Michael J. Hall, M.D., M.S., Chair, Department of Clinical Genetics at Fox Chase Cancer Center. "This is information I can immediately begin using for my patients to more accurately diagnose them and to better individualize their treatments."

About Caris Life Sciences Caris Life Sciences is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company's suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions.

Caris is also advancing precision medicine with Next Generation Profiling that combines its innovative service offerings, Caris Molecular Intelligence and ADAPT Biotargeting System, with its proprietary artificial intelligence analytics engine, DEAN, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides unmatched molecular solutions for patients, physicians, payers and biopharmaceutical organizations.

Whole transcriptome sequencing with MI Transcriptome provides the most comprehensive and unique RNA analysis available on the market and covers all 22,000 genes, with an average of 60 million reads per patient, to deliver extremely broad coverage and high resolution into the dynamic nature of the transcriptome. Assessing the whole transcriptome allows us to dig deeper into the RNA universe to uncover and detect fusions, splice variants, and expression changes that provide oncologists with more insight and actionable information when determining treatment plans for patients.

Caris Pharmatech, a pioneer of the original Just-In-Time research system with the largest research-ready oncology network, is changing the paradigm from the traditional physician outreach model to a real-time approach where patient identification is completed at the lab and the physician is informed so that the patient can be enrolled days earlier, and remain in the local physician's care, without having to travel to a large central trial site. This fundamentally redefines how pharmaceutical and biotechnology companies identify and rapidly enroll patients in precision oncology trials by combining Caris' highest quality industry leading large-scale molecular profiling services with Pharmatech's on-demand site activation and patient enrollment system.

Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visitwww.CarisLifeSciences.comor follow us on Twitter (@CarisLS).

About Ambry GeneticsAmbry Genetics, as part of Konica Minolta Precision Medicine, excels at translating scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. Our unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means we are first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions. We care about what happens to real people, their families, and the people they love, and remain dedicated to providing them and their clinicians with deeper knowledge and fresh insights, so together they can make informed, potentially life-altering healthcare decisions. For more information, please visitambrygen.com.

Caris Company Contact & Media:Srikant RamaswamiVice President, Chief Communications Officersramaswami@carisls.com +1-214-769-5510

Ambry Genetics Media Contact:Liz Squirepress@ambrygen.com (202) 617-4662

View original content to download multimedia:http://www.prnewswire.com/news-releases/caris-life-sciences-and-ambry-genetics-partner-to-advance-cancer-care-300968640.html

SOURCE Caris Life Sciences

The rest is here:
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care - BioSpace

DUBLIN, Dec. 4, 2019 /PRNewswire/ -- The "Global Hematologic Malignancies Testing Market: Focus on Product, Disease, Technology, End User, Region/Country Data and Competitive Landscape - Analysis and Forecast, 2019-2025" report has been added to ResearchAndMarkets.com's offering.

The market to grow at a significant CAGR of 15.24% during the forecast period, 2019-2025.

Growth in this market is driven by the rising incidence of hematologic malignancies, increasing adoption of inorganic growth strategies in the market, favorable reimbursement scenario in the global hematologic malignancies testing market, and increasing funding in hematologic malignancies testing market. The massive scope in the emerging economies and technological advancements in the field of molecular diagnostics are also expected to provide growth opportunities for players in the market.

The molecular discovery of disease-causing genes in blood cancers has led to the global phenomenon known as precision diagnostics in hematologic malignancies. By understanding the underlying molecular mechanisms of diseases and genetic composition and regulation in humans, molecular diagnostics have empowered physicians to move away from broadly classifying patients according to diseases, shifting toward individualized treatment, with the adoption of specialized kits, and services aimed at an early screening of disease.

The global hematologic malignancies testing market has witnessed significant growth, attributing to the increasing demand for multiple biomarker based-molecular diagnostics. The developments have been instrumental in improving the quality of life and reducing the cost and time of treatment, boosting the growth of the overall healthcare diagnostics market. Further, the increasing awareness and adoption of the precision diagnostic approach in developed as well as developing countries is the key driver for the growth of the global hematologic malignancies testing market.

The evolution of new technologies is enabling the acquisition of more information for more exhaustive characterization of the disease state, the most suitable treatment alternatives for a patient, or in the case of blood cancer, the rapid identification of a specific gene that could be responsible for a particular carcinoma.

Approaches that have the potential to address this requirement for highly increasing amounts of data include multi-marker or multiplexed approaches (methods that can test for multiple biomarkers in a single assay) and gene sequencing that enable the detection of multiple defects that are associated with a particular subset of patients with a disease. The practical application of these methods can be challenging owing to the complexity of the involved assays.

Key Questions Answered in this Report:

Key Topics Covered:

Executive Summary

1 Market Overview1.1 Introduction1.2 Historical Perspective1.3 Types of Hematologic Malignancy Diagnostic Tests1.4 Global Footprint1.5 Trends and Future Potential

2 Market Dynamics2.1 Market Drivers2.1.1 Rising Incidence of Hematologic Malignancies2.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market2.1.3 Favorable Reimbursement Scenario in the Global Hematologic Malignancies Testing Market2.1.4 Increase in Funding in Hematologic Malignancies Testing Market2.2 Restraints2.2.1 High Pricing Pressure2.2.2 Lack of Trained Professionals2.2.3 Issues Pertaining to the Analytical Validity of Genetic Testing for Cancers2.3 Market Opportunities2.3.1 Opportunities in the Emerging Economies2.3.2 Technological Advancements in the Field of Molecular Diagnostics

3 Competitive Landscape3.1 Key Strategies and Developments3.2 Product Scenario3.3 Funding Scenario3.4 Market Share Analysis3.5 Growth Share Analysis (Opportunity Mapping)3.6 Comprehensive Competitive Index

4 Industry Insights4.1 Regulatory Framework4.1.1 Legal Requirements and Framework in the U.S.4.1.2 Legal Requirements and Framework in Europe4.1.3 Legal Requirements and Framework in Asia-Pacific4.1.3.1 Japan4.1.3.2 China4.2 Reimbursement Scenario4.3 Physicians' Perceptions

5 Global Hematologic Malignancies Testing Market (by Product)5.1 Services5.2 Kits5.2.1 Gene Panels5.2.2 Molecular Clonality Testing5.2.3 Translocation Testing5.2.4 Mutation Testing5.2.5 Minimal Residual Disease (MRD) Testing

6 Global Hematologic Malignancies Testing Market (by Disease)6.1 Leukemia6.2 Lymphoma6.3 Multiple Myeloma6.4 Myeloproliferative Neoplasms6.5 Myelodysplastic Syndromes

7 Global Hematologic Malignancies Testing Market (by Technology)7.1 Next-Generation Sequencing (NGS)7.2 Polymerase Chain Reaction (PCR)7.3 Fluorescence in Situ Hybridization (FISH)7.4 Immunohistochemistry (IHC)7.5 Flow Cytometry7.6 Other Technologies

8 Global Hematologic Malignancies Testing Market (by End User)8.1 Specialty Clinics and Hospitals8.2 Diagnostic Laboratories8.3 Reference Laboratories8.4 Research Institutions

9 Global Hematologic Malignancies Testing Market (by Region)

10 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/r9y3z8

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-hematologic-malignancies-testing-market-2019-2025-increasing-adoption-of-inorganic-growth-strategies-in-the-market-300969229.html

SOURCE Research and Markets

Read the original here:
Global Hematologic Malignancies Testing Market 2019-2025: Increasing Adoption of Inorganic Growth Strategies in the Market - P&T Community

DUBLIN--(BUSINESS WIRE)--

The "Global Hematologic Malignancies Testing Market: Focus on Product, Disease, Technology, End User, Region/Country Data and Competitive Landscape - Analysis and Forecast, 2019-2025" report has been added to ResearchAndMarkets.com's offering.

Key Questions Answered in this Report:

Global Hematologic Malignancies Testing Market Forecast, 2019-2025

The hematologic malignancies testing market growth has been primarily attributed to the major drivers in this market such as rising incidence of hematologic malignancies, increasing adoption of inorganic growth strategies in the market, favorable reimbursement scenario in the global hematologic malignancies testing market, and increasing funding in hematologic malignancies testing market. However, there are significant challenges that are restraining the market growth. These challenges include high pricing pressure, lack of trained professionals, and issues pertaining to the analytical validity of genetic testing for cancers.

Scope of the Market Intelligence on Hematologic Malignancies Testing Market

The hematologic malignancies testing market report provides a holistic view of the market in terms of various factors influencing it, including product optimization, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the market. In addition, the study also includes exhaustive information on the unmet needs, perception of the new products, competitive landscape, market share of leading manufacturers, the growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global hematologic malignancies testing market.

Key Topics Covered:

Executive Summary

1 Market Overview

1.1 Introduction

1.2 Historical Perspective

1.3 Types of Hematologic Malignancy Diagnostic Tests

1.4 Global Footprint

1.5 Trends and Future Potential

2 Market Dynamics

2.1 Market Drivers

2.1.1 Rising Incidence of Hematologic Malignancies

2.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market

2.1.3 Favorable Reimbursement Scenario in the Global Hematologic Malignancies Testing Market

2.1.4 Increase in Funding in Hematologic Malignancies Testing Market

2.2 Restraints

2.2.1 High Pricing Pressure

2.2.2 Lack of Trained Professionals

2.2.3 Issues Pertaining to the Analytical Validity of Genetic Testing for Cancers

2.3 Market Opportunities

2.3.1 Opportunities in the Emerging Economies

2.3.2 Technological Advancements in the Field of Molecular Diagnostics

3 Competitive Landscape

3.1 Key Strategies and Developments

3.2 Product Scenario

3.3 Funding Scenario

3.4 Market Share Analysis

3.5 Growth Share Analysis (Opportunity Mapping)

3.6 Comprehensive Competitive Index

4 Industry Insights

4.1 Regulatory Framework

4.1.1 Legal Requirements and Framework in the U.S.

4.1.2 Legal Requirements and Framework in Europe

4.1.3 Legal Requirements and Framework in Asia-Pacific

4.1.3.1 Japan

4.1.3.2 China

4.2 Reimbursement Scenario

4.3 Physicians' Perceptions

5 Global Hematologic Malignancies Testing Market (by Product)

5.1 Services

5.2 Kits

5.2.1 Gene Panels

5.2.2 Molecular Clonality Testing

5.2.3 Translocation Testing

5.2.4 Mutation Testing

5.2.5 Minimal Residual Disease (MRD) Testing

6 Global Hematologic Malignancies Testing Market (by Disease)

6.1 Leukemia

6.2 Lymphoma

6.3 Multiple Myeloma

6.4 Myeloproliferative Neoplasms

6.5 Myelodysplastic Syndromes

7 Global Hematologic Malignancies Testing Market (by Technology)

7.1 Next-Generation Sequencing (NGS)

7.2 Polymerase Chain Reaction (PCR)

7.3 Fluorescence in Situ Hybridization (FISH)

7.4 Immunohistochemistry (IHC)

7.5 Flow Cytometry

7.6 Other Technologies

8 Global Hematologic Malignancies Testing Market (by End User)

8.1 Specialty Clinics and Hospitals

8.2 Diagnostic Laboratories

8.3 Reference Laboratories

8.4 Research Institutions

9 Global Hematologic Malignancies Testing Market (by Region)

10 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/polq31

View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005431/en/

View post:
Global Hematologic Malignancies Testing Market to 2025: Focus on Product, Disease, Technology, End User, Region/Country Data and Competitive Landscape...

Global Stem Cell Therapy Market Analysis

The recent report published by TMRR on the global Stem Cell Therapy market is an in-depth analysis of the overall prospects of the Stem Cell Therapy market in the upcoming years. The data collected from credible primary and secondary sources is accurately represented in the report backed up by relevant figures, graphs, and tables. The report includes a quantitative and qualitative analysis of the various aspects of the market by collecting data from the key participants in the Stem Cell Therapy market value chain.

The report reveals that the global Stem Cell Therapy market is set to grow at a CAGR of ~XX% over the forecast period (2019-2029) and surpass the value of ~US$XX by the end of 2029. The presented study also includes a thorough analysis of the micro and macroeconomic factors, regulatory framework, and current trends that are expected to influence the growth of the Stem Cell Therapy market during the assessment period.

Reports are available at cut-down rates for new customers! Offer expires soon!

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

Vital Information Enclosed in the Stem Cell Therapy Market Report:

Important Queries Addressed in the Report

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

Stem Cell Therapy Market Segmentation

The market study put forward by TMRR segments the global Stem Cell Therapy market to offer a microscopic understanding of the various aspects of the Stem Cell Therapy market. The Stem Cell Therapy market is segmented on the basis of region, product type, end-user, and more.

The study offers a Y-o-Y growth projection of each market segment and sub-segment over the stipulated timeframe of the study.

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Why Buy from TMRR?

Read more:
Stem Cell Therapy Market Size, Share, Trends, and Opportunity Analysis by 2017 - 2025 - The Market Expedition

Cryonics Technology market research report 2015-2024 helps businessman/investor avoiding unpleasant surprises. Intuition and experience can be helpful at times, but research and facts often paint a more accurate picture of your market. This Cryonics Technology market report presents a comprehensive overview, market shares, and growth opportunities of Cryonics Technology industry by product type, application, key manufacturers and key regions and countries.

The report firstly introduced the Cryonics Technology basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Look insights of Global Cryonics Technologyindustry market research report athttps://www.pioneerreports.com/report/200035

About Cryonics Technology Industry

The overviews, SWOT analysis and strategies of each vendor in the Cryonics Technology market provide understanding about the market forces and how those can be exploited to create future opportunities.

Key Players in this Cryonics Technology market are:

Get sample Copy of this Cryonics Technology Market Report athttps://www.pioneerreports.com/request-sample/200035

Production Analysis:SWOT analysis of major key players ofCryonics Technology industry based on a Strengths, Weaknesses, companys internal & external environments. , Opportunities and Threats. . It also includesProduction, Revenue, and average product price and market shares of key players. Those data are further drilled down with Manufacturing Base Distribution, Production Area and Product Type. Major points like Competitive Situation and Trends, Concentration Rate Mergers & Acquisitions, Expansion which are vital information to grow/establish a business is also provided.

Product Segment Analysis of the Cryonics Technology Market is:

Product Product Type Segmentation SegmentationSlow FreezingVitrificationUltra-Rapid

Industry SegmentationAnimal HusbandryFishery ScienceMedical SciencePreservation Of Microbiology CultureConserving Plant Biodiversity

End User SegmentationLife Science And Healthcare FacilitiesResearch Laboratorie

Look into Table of Content of Cryonics Technology Market Report at https://www.pioneerreports.com/TOC/200035

The scope of Cryonics Technology Market report:

Global market size, supply, demand, consumption, price, import, export, macroeconomic analysis, type and application segment information by region, including:Global(Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]

Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]

North America[United States, Canada, Mexico]

Middle East & Africa[GCC, North Africa, South Africa],

South America[Brazil, Argentina, Columbia, Chile, Peru])

Industry chain analysis, raw material and end users information

Global key players information including SWOT analysis, companys financial figures, Laser Marking Machine figures of each company are covered.

Powerful market analysis tools used in the report include: Porters five forces analysis, PEST analysis, drivers and restraints, opportunities and threatens.

Based year in this report is 2019; the historical data is from 2014 to 2018 and forecast year is from 2020 to 2024.

Inquire for further detailed information of Cryonics Technology Market Report at:https://www.pioneerreports.com/pre-order/200035

Manufacturing Analysis Cryonics Technology Market

Manufacturing process for the Cryonics Technology is studied in this section. It includes through analysis of Key Raw Materials, Key Suppliers of Raw Materials, Price Trend of Key Raw Materials, cost of Raw Materials & Labor Cost, Manufacturing Process Analysis of Cryonics Technology market

Marketing Strategy Analysis, Distributors/Traders Analysis of Cryonics Technology Market

Various marketing channels like direct and indirect marketing are portrayed in Cryonics Technology market report. Important marketing strategical data , Marketing Channel Development Trend, , Pricing Strategy, Market Positioning, Target Client Brand Strategy and Distributors/Traders List

In this study, the years considered to estimate the market size ofCryonics TechnologyMarket are as follows:-

No Of Pages in Cryonics Technology Market Report: 123

Single User Licence Price: USD 2350

Purchase Reportathttps://www.pioneerreports.com/checkout/200035

Cryonics Technologymarket reports deliver insight and expert analysis into key consumer trends and behaviour in marketplace, in addition to an overview of the market data and key brands.Cryonics Technologymarket reports provides all data with easily digestible information to guide every businessmans future innovation and move business forward.

See the article here:
Global Cryonics Technology Market Comprehensive Insights and Growth Potential In The Future - Northwest Arkansas Politics

YAKUTSK, Russia Russian scientists have shown off a prehistoric dog or wolf puppy, thought to be 18,000 years old, found in permafrost in the country's Far East.

Discovered last year in a lump of frozen mud near the city of Yakutsk, the puppy is unusually well-preserved, with its hair, teeth, whiskers and eyelashes still intact.

"This puppy has all its limbs, pelage fur, even whiskers. The nose is visible. There are teeth. We can determine due to some data that it is a male," Nikolai Androsov, director of the Northern World private museum where the remains are stored, said Monday at Yakutsk's Mammoth Museum, which specializes in ancient specimens.

Love Daln, a professor of evolutionary genetics at the Stockholm-based Center for Palaeogenetics, which took a piece of the puppy's bone to study its DNA, said it still couldn't be determined whether the puppy was that of a dog or a wolf.

Let our news meet your inbox. The news and stories that matters, delivered weekday mornings.

"That makes it even more interesting," Daln said.

In recent years, Russia's Far East has provided many riches for scientists studying the remains of ancient animals. As the permafrost melts, affected by climate change, more and more parts of woolly mammoths, canines and other prehistoric animals are being discovered. Often it is mammoth tusk hunters who discover them.

Download the NBC News app for breaking news

"Why has Yakutia come through a real spate of such unique findings over the last decade? First, it's global warming," Sergei Fyodorov, a scientist at North Eastern Federal University, told The Associated Press. "It really exists, we feel it, and local people feel it strongly. Winter comes later. Spring comes earlier."

The Center for Palaeogenetics has been studying the puppy's DNA for more than year. Further tests have left scientists with more questions than answers.

"The first step was, of course, to send the sample to radiocarbon dating to see how old it was, and when we got the results back, it turned out that it was roughly 18,000 years old," Daln said in an online interview.

"We have now generated a nearly complete genome sequence from it, and normally when you have a two-fold coverage genome, which is what we have, you should be able to relatively easily say whether it's a dog or a wolf, but we still can't say and that makes it even more interesting," Daln said.

He said scientists planned to conduct a third round of genome sequencing, which might solve the mystery.

Continue reading here:
18,000-year-old puppy found remarkably preserved in permafrost - NBCNews.com

If you buy something through a link on this page, we may earn a small commission. How this works.

Female hair loss can happen for a variety of reasons, such as genetics, changing hormone levels, or as part of the natural aging process.

There are various treatment options for female hair loss, including topical medications, such as Rogaine. Other options include light therapy, hormone therapy, or in some cases, hair transplants.

Eating a nutritious diet and maintaining a healthy lifestyle can also help keep hair healthy.

The Food and Drug Administration (FDA) approves Minoxidil to treat hair loss. Sold under the name Rogaine, as well as other generic brands, people can purchase topical Minoxidil over-the-counter (OTC). Minoxidil is safe for both males and females, and people report a high satisfaction rate after using it.

Minoxidil stimulates growth in the hairs and may increase their growth cycle. It can cause hairs to thicken and reduce the appearance of patchiness or a widening hair parting.

Minoxidil treatments are available in two concentrations: the 2% solution requires twice daily application for the best results, while the 5% solution or foam requires daily use.

While the instinct may be to choose the stronger solution, this is not necessary. Studies posted to the International Journal of Women's Dermatology and the Journal of the American Academy of Dermatology found that 2% minoxidil was effective for females with androgenetic alopecia, or pattern baldness.

If a person finds success with minoxidil, they should continue using it indefinitely. When a person stops using minoxidil, the hairs that depended on the drug to grow will likely fall out within 6 months.

Side effects from minoxidil are uncommon and generally mild. Some females may experience irritation or an allergic reaction to ingredients in the product, such as alcohol or propylene glycol. Switching formulas or trying different brands may alleviate symptoms.

Some females may also experience increased hair loss at first when using minoxidil. This typically stops after the first few months of treatment as the hair gets stronger.

Additionally, misapplying minoxidil or applying it to the forehead or too much of the neck may cause hair growth in these areas. Only apply minoxidil to the scalp to avoid these side effects.

Minoxidil is available to purchase in stores and online.

Low-level light therapy may not be sufficient treatment for hair loss on its own, but it may act to amplify the effects of other hair loss treatments, such as minoxidil.

A trial posted to the Indian Journal of Dermatology, Venereology, and Leprology found that compared to control groups, adding low light therapy to regular 5% minoxidil treatment for androgenetic alopecia helped improve the recovery of the hairs and the participants' overall satisfaction with their treatment.

Researchers will need to carry out further research to help strengthen these results.

The drug ketoconazole may help treat hair loss in some cases, such as androgenetic alopecia, where inflammation of the hair follicles often contributes to hair loss.

One review posted to the International Journal of Women's Dermatology noted that topical ketoconazole might help reduce inflammation and improve the strength and look of the hair.

Ketoconazole is available as a shampoo. Nizoral is the best known brand and is available for purchase over the counter and online. Nizoral contains a low concentration of ketoconazole, but stronger concentrations will require a prescription from a doctor.

Some females may also respond to corticosteroid injections. Doctors use this treatment only when necessary, for conditions such as alopecia areata. Alopecia areata results in a person's hair falling out in random patches.

According to the National Alopecia Areata Foundation, injecting corticosteroids directly into the hairless patch may encourage new hair growth. However, this not may prevent other hair from falling out. Topical corticosteroids, which are available as creams, lotions, and other preparations, may also reduce hair loss.

Early evidence suggests that injections of platelet-rich plasma may also help reduce hair loss. A plasma-rich injection involves a doctor drawing the person's blood, separating the platelet-rich plasma from the blood, and injecting it back into the scalp at the affected areas. This helps speed up tissue repair.

A recent review posted to Aesthetic Plastic Surgery noted that most studies suggest that this therapy reduces hair loss, increases hair density, and increases the diameter of each hair.

However, because most studies up until now have been very small, the review calls for more research using platelet-rich plasma for androgenic alopecia.

If hormone imbalances due to menopause, for example, cause hair loss, doctors may recommend some form of hormone therapy to correct them.

Some possible treatments include birth control pills and hormone replacement therapy for either estrogen or progesterone.

Other possibilities include antiandrogen medications, such as spironolactone. Androgens are hormones that can speed up hair loss in some women, particularly those with polycystic ovary syndrome, who typically produce more androgens.

Antiandrogens can stop the production of androgens and prevent hair loss. These medications may cause side effects, so always talk to the doctor about what to expect and whether antiandrogens are suitable.

In some cases where the person does not respond well to treatments, doctors may recommend hair transplantation. This involves taking small pieces of the scalp and adding them to the areas of baldness to increase the hair in the area naturally. Hair transplant therapy can be more costly than other treatments and is not suitable for everybody.

Some minor hair loss may happen due to clogged pores on the scalp. Using medicated shampoos designed to clear the pores from dead skin cells may help promote healthy hair. This may help clear minor signs of hair loss.

Massaging the scalp may increase circulation in the area and help clean away dandruff. This helps keep the scalp and hair follicles healthy.

The most common cause of hair loss in females is androgenetic alopecia, which has strong links to genetics and can run in families.

According to the International Journal of Women's Dermatology, hair loss from androgenetic alopecia may start at a young age. Some females may begin losing their hair in their late teens or early twenties, though most females may not begin to lose their hair until their 40s or older.

Both males and females can develop androgenetic alopecia, but they experience it in different ways. Males tend to experience a receding hairline or bald spot on top of their head, while females tend to present different symptoms.

In females, the parting at the center of the hair often becomes more defined or wider. Females may also experience thinning hairs, and hair may appear more thin or patchy overall.

These symptoms are due to a thinning of each hair strand. The hairs also have a shorter life cycle, and hairs only stay on the head for a shorter period.

Female pattern hair loss is a progressive condition. Females may only notice a slightly wider parting in their hair at first, but as symptoms progress, this can become more noticeable.

Other forms of alopecia, such as alopecia areata, may cause one or more patches of complete baldness.

Other factors may play a role in hair loss, such as inflammatory conditions that affect the scalp and hormone imbalances. Doctors may want to investigate these possible causes if the person does not respond to typical treatments.

While losing hair at a young age may be concerning, hair loss is a reality for many people as they age. One study posted to the Indian Journal of Dermatology, Venereology, and Leprology noted that up to 75% of females would experience hair loss from androgenetic alopecia by the time they are 65 years old.

While many females look for ways to treat hair loss while they are young, at some point, most people accept hair loss as a natural part of the aging process.

Some people may choose to wear head garments or wigs as a workaround to hair loss. Others work with their aging hair by wearing a shorter haircut that may make thin hair less apparent.

Hair loss can affect both males and females. Hair loss in females may have a range of causes, though the most common is androgenetic alopecia.

There are a variety of treatments for hair loss for females, including OTC hair loss treatments, which are generally effective. Anyone experiencing hair loss should visit their doctor who can diagnose any underlying factors.

If a doctor suspects there is another underlying cause or the person does not respond well to OTC treatments, they will look into other treatment options.

We picked linked items based on the quality of products, and list the pros and cons of each to help you determine which will work best for you. We partner with some of the companies that sell these products, which means Healthline UK and our partners may receive a portion of revenues if you make a purchase using a link(s) above.

Follow this link:
10 ways of treating female hair loss - Medical News Today

An 18,000-year-old puppy buried for centuries in a lump of frozen mud was unveiled on Monday by scientists who hope it can help bridge the connection between dogs and wolves.

The puppy, which was male, was discovered 18 months ago, preserved in a layer of permafrost in Siberias Far Eastern reaches, according to Dave Stanton, a research fellow at the Center for Palaeogenetics in Stockholm and one of the scientists who examined its DNA.

The fur, skeleton, teeth, head, lashes and whiskers of the pup, named Dogor, are still intact, he said. But scientists dont know whether it is a dog or wolf. Stanton said more DNA research would be conducted in the coming months. We need to put this information into context, he said in an interview.

Many scientists say dogs evolved about 15,000 years ago from a species of extinct wolves. Others suggest it could have happened much earlier, perhaps 30,000 years ago or more. These wolves evolved after generations of exposure to humans, were domesticated and became the canine companions we know today.

The puppy, which was found by locals, is being studied at North-Eastern Federal University in Yakutsk, the capital of Yakutia, a sprawling region in eastern Siberia that constitutes 20 per cent of Russia. (The puppy remains were found near Yakutsk.) Nikolai Androsov, director of the Northern World museum where the remains will be kept, presented the discovery on Monday, according to The Associated Press. Yakutia is known for its oil and gas reserves and abundance of diamond mines.

Several extinct animals have been found in the thick permafrost, in part because of the melting of ice resulting from climate change. They include a male steppe bison, a woolly rhinoceros, a mummified pony and several mammoths. Stanton said treasure seekers sometimes used water cannons to break through the permafrost to extract mammoth ivory tusks, which are later sold. It must have frozen quickly before scavengers could get to it, Stanton said of the puppy. We also found a lot of samples that were not well preserved. There seems to be natural traps in the landscape where animals are frozen before they decomposed.

He said the DNA used to date the puppy and figure out its gender was extracted from a rib bone. He said he was not sure if a necropsy was performed to see if its organs, including the heart and liver, were intact.

The body is well preserved, which is rare, Stanton said. Its the best Ive seen.

Modern dogs are not like modern wolves. Wolves are reticent to eat in front of people, for example, while domesticated dogs beg for dinner table scraps. Their physiology is different, with dogs having shorter snouts and wider skulls. And male wolves participate in pup raising, while male dogs generally avoid it.

Stanton said the dating of the dog was done at Oxford University, and he and his colleagues will continue to collaborate with scientists at North-Eastern Federal University. We need to look at more samples from that time period, he said. Then we will be able to understand if it was a dog or a wolf. New York Times

Here is the original post:
Dog or wolf? Frozen 18,000-year-old puppy gives scientists pause - The Irish Times

The title metaphor of my new novel, The Stone Boys, is of a boy who must become hard like stone to survive childhood sexual abuse. As an adult, he may function well for large chunks of time, even marrying, being intimate, raising children; but his internal resources are thin, and he rarely has any choice, if untreated, but to resort to hardening up against relationships, especially those that become close.

I was one of the stone boys. At ten years old, in 1968, my psychiatrist molested me over a period of six months, first grooming me, then moving to abuse. After I escaped him, my confusion, shame and terror had no outlet except into signs of trauma that adults at the time did not recognize as abuse-trauma for two reasons: I did not disclose the abuse until I was 18, and in 1968, the signs were not public enough for people to know about them.

My client, Tom, had some of the same signs I had. In my office, he said, Ive never been very good at relationships, and reading your Stone Boys book, I think I finally understand why. Its so obvious, but I missed it.

Whats obvious?

Tom had been married and divorced twice, had difficulty holding down jobs, and had been in and out of rehab.

Well now, antsy, he stood up out of the chair; I asked if we should go take a walk together, to which he agreed. At a local park, we sat down on a bench.

Did the story trigger memories? I asked. He nodded his head but didnt speak.

You can tell me, I said. Im safe, were confidential, and you know I will get what youre saying. You know Ive been there, in my own way.

I know, he acknowledged, standing back up again. We walked again in silence for a while, returning to my office where, once the door was closed, he told me his story. His abuse had been even more brutal than mine.

***

By now, most or all therapists are familiar with the ACEs (Adverse Childhood Experiences) survey, a very useful tool for trauma-informed counseling. I have also developed my own relationship-based checklist for my clients. Tom had eight of these Signs of Unresolved Childhood Abuse Trauma in Adult Relationships.

Treating Abused Boys and Men

A first step in treating males especially is Personal Storytelling. Even if a therapist has never experienced sexual abuse trauma, all of us have experienced trauma of some kind: some form of storytelling about trauma in your own life can help males to open themselves up.

A second step is recognition that sexual abuse for males is indeed different than for females (in most cases), not only in the myriad ways males and females are neurobiologically different but in the specific male confusion over pleasure. Most sexual abuse of males, though not all, involves male ejaculation, something that gives pleasure. Much less often does the abused girl experience an orgasm. With Tom, talking about this helped him sort through guilt and shame at deep levels.

More Best Practices for the Abuse Survivors and Their Therapists

For abused males, these are best practices I have relied upon and will likely be needed as ongoing mechanisms for healing.

Therapy, Medication, Brain-Direct Modalities EMDR (Eye Movement Desensitization Reprocessing), Neurofeedback, mindfulness, meditation, prayer, spiritual dialogue (talking directly with God), and ongoing talk therapy.

Ongoing Support Groups Getting men involved in support groups, mentoring/counseling by and with males, and groups and counseling with people from their own milieu (racial, sexual orientation, culture, similar religious background) who have also been traumatized.

Couples Therapy Because nearly everyone who has been sexually traumatized has relational difficulties of some kind, these men often need couples/relational therapy as soon as possible.

Addiction Work Many abuse victims also possess addiction genetics which get triggered by the abuse. Recovery groups and addiction therapy can be crucial.

Choice Theory Because an abuse survivor has felt out-of-control during the months or years of trauma, it is important to give him choices and control now, years later.

Help Him Avoid Rumination Loops Negative rumination loops may be precursors to severe depression and actions taken (What should I do!), especially in a mans islands of competence, can help.

Journaling Writing or video journaling can lead to more rumination, so it can backfire, but often it is a good tool for boys and men who lean already toward reading, tech, and/or verbal processing.

Organizations That Can Provide Support

National Sexual Assault Helpline. 800.656.HOPE (4673).Department of Defense Helpline. (877) 995-5247.SAMHSA (Substance Abuse and Mental Health Services Administration).

Additional Reading

The Stone Boys, Michael Gurian, Latah Books, 2019.Saving Our Sons, Michael Gurian, GI Press, 2017Victims No Longer, Mike Lew, HarperPerennial, 2004.Abused Boys, Mic Hunter, Ballantine, 1991Beyond Betrayal, Richard Gartner, John Wiley, 2005.

File under:The Art of Psychotherapy,Child & Adolescent Therapy

Read this article:
Counseling the Stone Boys: Helping Boys and Men Who Have Been Sexually Abused - Psychotherapy.net

Male babiesborn to older mothers have a higher risk of heart problems because the placenta doesn't work as well,according to a study on rats.

The study was conducted by the University of Cambridgeandpublished in the journalScientific Reports. Itfound that changes in the placentas of older mothers could damage the health of male babies, according to Science Daily. Older mothers in the research were the rat equivalent of a pregnant woman aged 35 or older, which is considered a geriatric pregnancy. Rats are usedsince their biology is similar to humans'.

PREVIOUSLY:Study Finds Older Mothers Are More Likely To Birth Multiples

The research showed that male babies suffered negative consequences of the late birth, while females did not. In fact, in certain cases, the females even appeared to benefit. The researchers said placentas became less efficient at transporting nutrients and oxygen to foetuses as the mothers got older.

"With the average age of first pregnancy in women becoming higher and higher, it is very important to understand how the age of the mother and the sex of the baby interact to determine pregnancy and later-life health of the child," said Dr. Amanda Sferruzzi-Perri.

According to the researchers, the placenta, which connects mother to baby in the womb, is 'highly dynamic'. They added that genetic changes in a woman as she ages could affect how the placenta functions. It was also found that babies of either sex did not grow as large in the placentas of older women. And the males were more likely to have high blood pressure or heart problems as they grew older because the mother's had a different internal shape and became less efficient. However, female babies did not suffer the same risk.

The scientistsrevealed that, in the combination of older mother and female baby, the placenta actually "showed beneficial changes in structure and function that would maximise the support of fetal growth". Similar discoveries about males have been made before but it was not well understood why they were at a particular disadvantage. The new research shows the genes involved in the older mother-male baby mix make the placenta less able to do its job.

According to Cambridge's Dr. Tina Napso: "A pregnancy at an older age is a costly proposition for the mother, whose body has to decide how nutrients are shared with the fetus. That's why, overall, fetuses do not grow sufficiently during pregnancy when the mother is older compared to when she is young. We now know that growth, as well as gene expression in the placenta is affected in older mothers in a manner that partially depends on sex: changes in the placentas of male fetuses are generally detrimental."

READ NEXT:Research Finds Link Between Proinflammatory Diet During Pregnancy & Wheezing In Childhood

High Androgen Levels During Pregnancy Can Increase The Risk Of Polycystic Ovarian Syndrome For Generations

View post:
Placenta Changes May Mean Male Babies Of Older Women Likely To Have Heart Problems - BabyGaga

Get great content like this right in your inbox.

Amazon kept up its tradition on Cyber Monday.

The online giant said that Cyber Monday was the single biggest shopping day in its history, based on the number of items ordered worldwide. Cyber Monday has been Amazon's top sales day for several years, outpacing the previous Prime Day and Black Friday. Amazons best-selling products on Cyber Monday in the U.S. included Echo Dot, Fire TV Stick with Alexa Voice Remote, Play-Doh Sweet Shoppe Cookie Creations, Keurig K-Cafe Coffee Maker and Lego City Ambulance Helicopter 60179 Building Kit.

In keeping with its policy of rarely (if ever) revealing exact numbers, Amazon said that hundreds of millions of products were ordered worldwide between Thanksgiving and Cyber Monday. Shoppers purchased millions more Amazon devices over the holiday period compared to the same period last year, the said, with Echo Dot and Fire TV Stick 4K with Alexa Voice Remote ranking as the top-selling items.

In other holiday weekend highlights from Amazon:

Read the original post:
Amazon set a record of its own on Cyber Monday - Chain Store Age

Its known as the silent killer.Symptoms begin with muscle weakness until eventually ones muscles are completely deteriorated.Its called muscular dystrophy, andit affects one in every 5,000 males.

Because it is rare, muscular dystrophy has not received the attention and research funding of more common diseases, according to University of Cincinnati researchers.

My experience is that if a person does not have a family member or relative or friend affected by muscular dystrophy, then they typically do not know about [muscular dystrophy], saysHani Kushlaf, associate professor of neurology and pathology, who sees patientswith the disease.

UC researchers are trying to change this lack of transparency by sharing their experiences with the disease. They understand that the goal of finding a cure for muscular dystrophy begins with awareness.

One person who truly understands the disease from both a medical professional standpoint and from personal experience is John Quinlan, director of the neuromuscular center at UCs Neuroscience Institute, who teaches as a professor and sees patients as a practicing neurologist with UC Health.

In an interview with UC Health, Quinlan said he chose neurology because he believed it was a field where there was a lot of puzzle-solving of complicated diagnoses such as his own muscular dystrophy.

Because I have some physical limitations, I saw when I was a medical student that I wasnt going to go into surgical areas, and so that made me think of the more internal medicine and subspecialties, Quinlan said.

Phillip Witcher, who is completing his doctorate at the College of Medicine, had Quinlan as a professor. He said he didnt know Quinlan had muscular dystrophy when he met him.

I just knew that he was in a wheelchair and that he was a smart professor, Witcher said.

Witcher himself is doing research on muscular dystrophy. He is in his first year of research on muscle cell fusion in the Doug Millay lab at Cincinnatis Childrens Hospital.

Witchers research focuses on themyomaker and myomergerm the proteins within muscular cells with the hope of helping patients with muscular dystrophy through cell therapy.

Muscular Dystrophy is caused bygenetic mutationsthat interfere with the production of proteins that are needed to build and maintain healthy muscles, according to the Muscular Dystrophy Association (MDA).

Imagine running a race. Your muscles are tired, and to recover they need to build new proteins to regain strength.The feeling for patients with muscular dystrophy is similar, except they never regain it. The reason muscular dystrophy is known as the silent killer is that this muscle deterioration is a slow process. The body gradually evolves into a physical shell.

Muscle weakness often leads to the curving of the spine, forcing many with it into a wheelchair if their failing muscles didnt force them into one already.It leads to the shortening of muscles and tendons and severe breathing issues. Eventually this advances to paralyzed mobility in most of the body. There is no cure.

One of the most intense and aggressive forms of muscular dystrophy is Duchenne Muscular Dystrophy (DMD). Muscle loss and weakness is caused by alterations ina protein calleddystrophin, which helps keep muscle cells whole. Symptoms for those who have DMD first present themselves in children at an early age and progressively get worse.

But today, people with DMD have a longer lifespan because research breakthroughs have created drugs and treatment options. Symptoms can kill. These treatment options help with treating the symptoms from muscular dystrophy. According to MDA,the life expectancy for those born with DMD is in the early 30s because of advances in cardiac and respiratory care.

We live in an exciting time for (treating) muscular dystrophies, Kushlaf said.

UC researchers agree: to find a cure, awareness needs to be shared and stories need to be told.

Witcher said diseases with more physical and behavioral cues, such as breast cancer, get media attention. Millions of people see the physical signs of chemotherapy of breast cancer patients, such as hair loss and are the Susan G. Komen Breast Cancer Foundation, the largest and best-funded cancer organization.

I dont think it is just the lack of awareness, Kushlaf said. Federal funding for research is typically allocated for common disorders more than rare disorders. Therefore, researchers of common diseases are more likely to get funded than those who study rare diseases.

Still, Kushlaf said awareness for Amyotrophic Lateral Sclerosis (ALS) increased during the viral ALS bucket challenge, which led to significant philanthropy and funding of ALS research projects.

Kushlaf said researchers are hopeful of a cure. The FDA approval of gene therapy for spinal muscular atrophy offer hope for a cure or significant improvements, he said. The next steps are to find out the effect of gene therapies on muscular dystrophies.

Curing muscular dystrophy is a complex dilemma, as the problem lies in the genetic makeup of the individual, Kushlaf said. The advent of gene therapy offers hope for a cure.

Previous therapies have had limited success because they only helped slow the progression of the dystrophy, according to Kushlaf.

Witcher said therapies for muscular dystrophy have evolved, but most are only treating symptoms and not the disease itself.

And thats where were really stuck right now figuring out how to move forward as far as treating the disease and not just the symptoms, Witcher said.

See the original post:
Finding strength in the fight against muscular dystrophy - The News Record

BORIS Johnsons punishing 16-hour days are fuelled by porridge, flapjacks and endless cups of coffee.

He has also given up booze and confesses he reads ancient Greek poetry before bed.

The Sun spent a full day on the campaign trail with the PM, as he criss-crossed the country in a bid to whip up votes.

For our Day in the Life video diary, Mr Johnson confided about everything from organising a Nato summit to the personal abuse he gets from actor Hugh Grant.

On December 12, Mr Johnson will either get majority he craves to deliver Brexit, or be the second shortest-serving PM in history. With so much at stake, he packs in as much as he can to his breakneck daily campaigning schedule:

6.10am: Boris walks Jack Russell Dilyn then eats a large bowl of porridge at the flat he shares with his girlfriend Carrie Symonds at No11 Downing Street.

After breakfast he takes his first phone calls from four key aides and swaps text messages with confidante Cabinet ministers.

8am: He leaves leaves Downing Street for the nearby Conservative HQ. Election campaign director Isaac Levido has been at his desk from 5am and briefs Mr Johnson on daily tactics to attack Labour.

11am: A motorcade rushes the PM across central London so he can attend a vigil for the victims of the London Bridge terror attack. He is joined by Home Secretary Priti Patel, London Mayor Sadiq Khan and Labour leader Jeremy Corbyn.

The mornings campaign schedule was ripped up to allow politicians to pay their respects.

11.35am: An 81-mile dash down the M3 to Southampton. The PMs motorcade drives at high speed, bumper to bumper, repeatedly accelerating and braking heavily. But Mr Johnson insists he never gets car sick, saying: Im really too busy writing speeches, or thinking about the next thing.

Those guys on the motorbikes are brilliant though, what they do to get us through traffic fast. I do feel a bit ashamed sometimes, but it is essential. You just need to get from A to B fast.

1.10pm: A tour of Southamptons port taking in the control room and dockside where he meets workers, then out in a patrol boat to inspect ships at berth. Southampton Itchen is a key marginal, which the Tories held by just 31 votes in 2017.

Boris says he loves getting out, and takes every opportunity he can to promote Brexit. He declares: "When a big ship comes into this port, they make no distinction whether it comes from the EU or anywhere else in the world.

The procedures are exactly the same. It just goes to show that some of the anxiety about leaving the EU is very often overdone.

2.45pm: A round of local and national TV interviews. Campaign chiefs ensure he does this every day to dominate the news cycle. Mr Johnson faces questions on the London Bridge horror and pro-Remain actor Hugh Grant, campaigning for Lib Dems.

How does he feel when Grant, who played the Prime Minister in Love Actually, says the election is a national emergency and a Tory majority would be catastrophic?

Boris insists: Water off a ducks back. Of course a lot of people care very strongly about Brexit. I make an exception for the gentleman you mention, but most people I meet are frustrated about the paralysis in Parliament.

3.10pm: Before returning to London, the PM is briefed on the days developments for the Government. A senior No10 official always accompanies him on campaign trips in case there are any urgent decisions which need to be made. How does he handle constantly spinning all those plates?

Boris explains: I find it constantly stimulating. Obviously there is a different level of focus. Some of the geopolitical stuff does require a different tone and a different pitch. But what youre really doing is trying to bring people together.

5.15pm: Boris is back at Tory HQ in Westminster, for a meeting with senior Government officials about the upcoming Nato summit which Britain is hosting.

He sees his job this week as both cheerleader and peacemaker and says: Some people want to chip a bit of paint off Nato every now and then. Not everybody in France has been an uncritical admirer, so we have to show why it works.

6.10pm: The PMs motorcade heads 68-miles to Colchester, where he will address a Tory rally. He has been at it for ten hours. How does he keep going?

The PM admits: I sometimes succumb to flapjacks, which are not medically recommended. And I seem to be able to drink an unlimited amount of coffee without impeding my ability to sleep at the end of the day.

He insists that he seldom tires, describing himself as hard as nails and built from steel springs. Mr Johnson adds: I have a lot of energy. I think its genetic.

8.35pm: Traffic out of London is heavy and Boris is late for the rally at a Colchester printworks. Adoring party members cheer and laugh at his regular jokes. How does he pump himself up?

Boris says: I have a huge sense of responsibility for getting this right. This is it. There is a very short time left. There is a very real risk of another hung Parliament. On the way out two workers with mohicans, accost him for a selfie.

Live Blog

ELECTION NEWS Voters back Boris Johnson's tough defence stance as he hosts NATO leaders

CUT DOWN TO SIZE Corbyn humiliated after failing to confront Trump over NHS trade deal

ALL THE PRESIDENT'S FRIENDS Trump welcomed by the Queen and Charles at Buckingham Palace

ALL ABOARD Boris plans to plough 4.2bn into overhauling England's trains and bus services

POLL POSITION General Election polls tracker and odds - who will win in 2019?

10.20pm: His armour-plated Jaguar pulls up at the back entrance of No11 and Boris is home. What does he do to relax in those few moments before bed?

He gives an embarrassed giggle: A few quadratic equations, and a bit of Greek lyric poetry. Nothing complicated. Its a terrible confession but I do. Everybody should. Most might pour a stiff drink but Boris insists his self-imposed booze ban is still firmly in place.

He insists: Ive had to wet my whistle three times in this campaign but I will not swallow. I cant. We have to get Brexit done, unleash the potential. He turns and says: Night night, see you.

Read this article:
The Sun joins Boris Johnsons gruelling 16-hour day on the campaign trail - The Sun

news, latest-news

Russian scientists have showed off a prehistoric puppy, believed to be 18,000 years old, that was found in permafrost in the country's Far East. Discovered in 2018 in a lump of frozen mud near the city of Yakutsk, the puppy is unusually well preserved, with its hair, teeth, whiskers and eyelashes still intact. "This puppy has all its limbs, pelage - fur, even whiskers. The nose is visible. There are teeth. We can determine due to some data that it is a male," Nikolai Androsov, director of the Northern World private museum where the remains are stored, said at the presentation at the Yakutsk's Mammoth Museum which specialises in ancient specimens. In recent years, Russia's Far East has provided many riches for scientists studying the remains of ancient animals. As the permafrost melts, affected by climate change, more and more parts of woolly mammoths, canines and other prehistoric animals are being discovered. Often it is mammoth tusk hunters who discover them. "Why has Yakutia come through a real spate of such unique findings over the last decade? First, it's global warming. It really exists, we feel it, and local people feel it strongly. Winter comes later, spring comes earlier," Sergei Fyodorov, scientist with the North Eastern Federal University, told The Associated Press. "And the second very serious, deep reason, of why there a lot of finds is the very high price of mammoth tusk in the Chinese market." When the puppy was discovered, scientists from the Stockholm-based Centre for Palaeogenetics took a piece of bone to study its DNA. "The first step was of course to send the sample to radio carbon dating to see how old it was and when we got the results back it turned out that it was roughly 18,000 years old," Love Dalen, professor of evolutionary genetics at the center, said in an online interview. Further tests, however, left the scientists with more questions than answers - they could not definitively tell whether it was a dog or a wolf. Dalen said scientists were about to do a third round of genome sequencing, which might solve the mystery. Australian Associated Press

https://nnimgt-a.akamaihd.net/transform/v1/crop/frm/silverstone-feed-data/4ec5d096-b112-41b6-be92-003b2d13de51.jpg/r0_74_800_526_w1200_h678_fmax.jpg

December 3 2019 - 11:46AM

Russian scientists have showed off a prehistoric puppy, believed to be 18,000 years old, that was found in permafrost in the country's Far East.

Discovered in 2018 in a lump of frozen mud near the city of Yakutsk, the puppy is unusually well preserved, with its hair, teeth, whiskers and eyelashes still intact.

"This puppy has all its limbs, pelage - fur, even whiskers. The nose is visible. There are teeth. We can determine due to some data that it is a male," Nikolai Androsov, director of the Northern World private museum where the remains are stored, said at the presentation at the Yakutsk's Mammoth Museum which specialises in ancient specimens.

In recent years, Russia's Far East has provided many riches for scientists studying the remains of ancient animals.

As the permafrost melts, affected by climate change, more and more parts of woolly mammoths, canines and other prehistoric animals are being discovered. Often it is mammoth tusk hunters who discover them.

"Why has Yakutia come through a real spate of such unique findings over the last decade? First, it's global warming. It really exists, we feel it, and local people feel it strongly. Winter comes later, spring comes earlier," Sergei Fyodorov, scientist with the North Eastern Federal University, told The Associated Press.

"And the second very serious, deep reason, of why there a lot of finds is the very high price of mammoth tusk in the Chinese market."

When the puppy was discovered, scientists from the Stockholm-based Centre for Palaeogenetics took a piece of bone to study its DNA.

"The first step was of course to send the sample to radio carbon dating to see how old it was and when we got the results back it turned out that it was roughly 18,000 years old," Love Dalen, professor of evolutionary genetics at the center, said in an online interview.

Further tests, however, left the scientists with more questions than answers - they could not definitively tell whether it was a dog or a wolf.

Dalen said scientists were about to do a third round of genome sequencing, which might solve the mystery.

Australian Associated Press

Original post:
18000-year-old puppy found in permafrost - The Canberra Times

Glenn Gaudette, William Smith Deans Professor of Biomedical Engineering at Worcester Polytechnic Institute (WPI), has been named a fellow of theNational Academy of Inventors(NAI), the organization announced today. Gaudette is the founding director of the WPI Myocardial Regeneration Lab, where he has pioneered the use of plants as scaffoldingfor heart regeneration.

The NAI Fellows Program highlights academic inventors who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society. Election to NAI Fellow is the highest professional distinction accorded solely to academic inventors.

I am honored and humbled to be selected as a Fellow of the NAI. This prestigious recognition is a reflection of amazing collaborators, fantastic students, risk-taking funding organizations and a supportive family that I have been fortunate to benefit from, said Gaudette. Today, significant engineering and science advancements require a focus on creating value for society, work that flourishes in an open and collaborative environment like the one I enjoy at WPI.

As director of the Myocardial Regeneration Lab, Gaudette focuses broadly on cardiovascular regeneration techniques, but more specifically on developing better ways to deliver cells to damaged myocardium as well as better techniques to analyze cardiac mechanics. He has authored over 75 publications, including a co-edited book on cardiovascular regeneration, has four issued patents, and founded a company based on the technology developed in his laboratory. His research, which is supported by the National Institutes of Health and the National Science Foundation, aims to develop a treatment for the millions of Americans suffering from myocardial infarction and other cardiovascular diseases.

As a member of the NAI 2019 Fellows, Gaudette joins 168 educators and researchers representing 136 universities and governmental and nonprofit research institutes worldwide. Collectively, they hold over 3,500 issued U.S. patents. Among the 2019 Fellows are six recipients of the U.S. National Medal of Technology & Innovation or U.S. National Medal of Science and four Nobel Laureates, as well as recipients of other honors and distinctions. Their collective body of research covers a range of scientific disciplines including neurobehavioral sciences, horticulture, photonics and nanomedicine.

To date, NAI Fellows hold more than 41,500 issued U.S. patents, which have generated over 11,000 licensed technologies and companies, and created more than 36 million jobs. In addition, over $1.6 trillion in revenue has been generated based on NAI Fellow discoveries.

On April 10, 2020, the 2019 NAI Fellows will be inducted at the Heard Museum in Phoenix, Arizona as part of the Ninth Annual NAI Meeting. Laura A. Peter, Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the United States Patent and Trademark Office (USPTO),will provide the keynote address for the induction ceremony. At the ceremony, Fellows will be formally inducted by Peter and NAI President Paul R. Sanberg in recognition of their outstanding achievements.

In addition to being named an NAI Fellow, Gaudette is a Fellow of the American Institute for Medical and Biological Engineering. His teams research usingspinach leavesas scaffolds for growing human heart cells has been featured by media outlets throughout the world, including the BBC, theWashington Post,and Time.com. The work was named one of the top medical breakthroughs of the year byBoston Magazineand was the seventh most popular story of 2017 inNational Geographic. He has also worked on a novel technology using fibrin sutures to deliver stem cells to targeted areas of the body to repair diseased or damaged tissue, including cardiac muscle damaged by a heart attack.Outside the lab, Gaudette teaches biomedical engineering design and innovation, biomechanics and physiology. He promotes the development of the entrepreneurial mindset in his students through support provided by the Kern Family Foundationand serves as the director of the Value Creation Initiative at WPI.In 2015, he was named Faculty Member of the Year by the Kern Entrepreneurial Engineering Network (KEEN).

Go here to read the rest:
Professor Recognized For Cardiac Regeneration Research - WPI News

A new study released today in STEM CELLS outlines how fat grafting - which previous studies have shown can reduce and even reverse fibrosis (scar tissue) buildup - also improves the range of motion of the affected limb. The study, conducted by researchers at Stanford University School of Medicine, was conducted on mice.

DURHAM, N.C., Dec. 3, 2019 /PRNewswire-PRWeb/ --A new study released today in STEM CELLS outlines how fat grafting which previous studies have shown can reduce and even reverse fibrosis (scar tissue) buildup also improves the range of motion of the affected limb. The study, conducted by researchers at Stanford University School of Medicine, was conducted on mice.

The tumor-destroying capabilities of radiation therapy can be a life saver for a person suffering from cancer. But it's a therapy that has several unwanted side effects, too, including causing substantial damage not just to cancerous cells, but any healthy tissue in its path. Over time, fibrosis builds up in the treated area which, in the case of an arm, shoulder, or leg, for example, can lead to painful contractures that significantly limit extensibility and negatively impact the person's quality of life.

The Stanford team irradiated the right hind legs of subject mice, which resulted in chronic fibrosis and limb contracture. Four weeks later, the irradiated limbs of one group of the mice were injected with fat enriched with stromal vascular cells (SVCs). These potent cells already naturally exist in fat, but supplementation of fat with additional SVCs enhances its regenerative capabilities. A second group was injected with fat only, a third group with saline and a fourth group received no injections, for comparison. The animals' ability to extend their limb was then measured at baseline and every two weeks for a 12-week period. At the end of the 12 weeks, the hind limb skin underwent histological analysis and biomechanical strength testing.

"Each animal showed significant reduction in its limb extension ability due to the radiation, but this was progressively rescued by fat grafting," reported corresponding author Derrick C. Wan, M.D., FACS. Fat grafting also reduced skin stiffness and reversed the radiation-induced histological changes in the skin.

"The greatest benefits were found in mice injected with fat enriched with SVCs," Dr. Wan added. "SVCs are easily obtained through liposuction and can be coaxed into different tissue types, where they can support neovascularization, replace cells and repair injured issue.

"Our study showed the ability of fat to improve mobility as well as vascularity and appearance," he continued. "We think this holds enormous clinical potential especially given that adipose tissue is abundant and can be easily collected from the patients themselves and underscores an attractive approach to address challenging soft tissue fibrosis in patients following radiation therapy."

Furthermore, said co-author and world-renowned breast reconstructive expert Arash Momeni, M.D., FACS, "Our observations are potentially translatable to a variety of challenging clinical scenarios. Being able to reverse radiation-induced effects holds promise to substantially improve clinical outcomes in implant-based as well as autologous breast reconstruction. The study findings are indeed encouraging as they could offer patients novel treatment modalities for debility clinical conditions.

"Excessive scarring is a challenging problem that is associated with a variety of clinical conditions, such as burn injuries, tendon lacerations, etc. The potential to improve outcomes based on treatment modalities derived from our research is indeed exciting," Dr. Momeni added.

"Skin and soft tissue scarring and fibrosis are well-established problems after radiation. The current study, showing that human fat grafting can normalize the collagen networks and improve tissue elasticity in immune deficient mice, provides molecular evidence for how fat grafting functions," said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS. "The studies indicate that, with the appropriate regulatory approvals, autologous fat grafting could potentially also help human patients recover from radiation-induced tissue fibrosis."

The full article, "Fat grafting rescues radiation-induced joint contracture," can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/stem.3115.

Story continues

About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS (http://www.StemCells.com) is the world's first journal devoted to this fast paced field of research. THE ONCOLOGIST (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

SOURCE STEM CELLS

Read more:
Fat grafting improves range of motion in limbs damaged by radiation therapy - Yahoo Finance

Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science

Mont-Saint Guibert, Belgium, 4 December, 2019: Novadip Biosciences (Novadip or the company), a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform to generate multiple product candidates, announces that it is presenting data in a series of presentations at the 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science (IFATS) taking place in Marseille, France, from 4-7 December 2019.

Dr Denis Dufrane, Chief Scientific Officer and co-founder, Novadip, commented: The findings that will be presented at IFATS highlight the capabilities of Novadips 3-dimensional, scaffold-free extracellular matrix (ECM) technology platform utilizing adipose-derived stem cells (ASCs) to generate product candidates to address critical size bone and skin reconstruction, as well as our manufacturing capabilities and expertise. We look forward to progressing our clinical programmes and generating further data in support of our unique platform as we look to address hard and soft tissue reconstruction for patients who have limited or no treatment options.

Novadip will deliver five oral presentations and one video presentation. Details of the presentations and short summaries are below.

Genetic stability assessment in bone tissue-engineered productsCline Pierard, oral presentation #8 (abstract 1395), 5 December 2019, 8:38 am CET

The presentation will discuss the different analytical approaches to predict the genetic behavior over the entirety of the manufacturing process for the companys product candidates for bone reconstruction.

A scaffold-free graft for large critical size bone defect: preclinical evidence to clinical proof of conceptSophie Veriter, video presentation #V5 (abstract 1363), 5 December 2019, 2:48 pm CET

The session will discuss how the scaffold-free 3D-graft (comprised of ASCs) plays a major role promoting ASCs engraftment and to induce osteogenesis in a fibrotic environment and promote bone fusion in a critical-sized bone defect.

The in vivo immunogenicity of a human 3D scaffold-free tissue engineered product for bone reconstruction: a xenogenic modelGatan Thirion, oral presentation #30 (abstract 1382), 5 December 2019, 4:30 pm CET

Detail will be provided on how the human scaffold-free 3D approach, in a xenogenic model, can elicit a specific anti-human immune response but can maintain the potential of in vivo osteogenicity.

An allogenic 3D scaffold-free tissue engineered product for deep thickness skin regeneration: in vitro development to in vivo proof of conceptSophie Veriter, oral presentation #88 (abstract 1317), 6 December 2019, 5:50 pm CET

The presentation will discuss how the scaffold-free approach with the allogenic 3D-graft (derived from ASCs) demonstrated safety and efficacy in a stringent xenogenic model of hyperglycemic and ischemic deep-thickness wound.

Allogenic 3D scaffold-free tissue engineered product for deep thickness skin regeneration: in vitro characterization and in vivo biocompatibilityValrie Lebrun, oral presentation #90 (abstract 1341), 6 December 2019, 6:06 pm CET

The presentation will provide an overview on how the allogenic scaffold-free 3D-graft improves ASC bioactivity for the angiogenesis and in vivo remodeling by the specific ECM-proteins of wound healing.

Monitoring of cell culture conditions and early prediction of the quality of an osteogenic cell-based medicinal productAnas Namur, oral presentation #136 (abstract 1392), 7 December 2019, 2:44 pm CET

The session will describe how cellular metabolism was studied throughout the companys manufacturing process to better understand the physiology of the proliferative and differentiated cells and subsequently develop predictive tests focused on critical attributes of the final product.

To view the full abstracts, please follow this link.

The full list of abstracts can be found here. Further information on IFATS is available here.

- Ends -

Notes to editors

Novadip Biosciences

Novadip Biosciences is a clinical stage biopharmaceutical company leveraging its unique 3D tissue regeneration technology platform to generate multiple product candidates to address hard and soft tissue reconstruction for patients who have limited or no treatment options. The companys proprietary 3M3 platform is a 3-dimensional, extracellular matrix that utilizes adipose-derived stem cells to deliver highly-specific growth factors and miRNA to mimic the physiology of natural healing and creates a range of products that address specific challenges in tissue regeneration. Novadips initial focus is on critical size bone reconstruction and its lead program is in development for a rare pediatric orthopedic disease. The company is also applying its 3M3 platform to develop truly novel off-the-shelf/allogeneic therapies to address more prevalent tissue defects. For more information, visit http://www.novadip.com .

For further information, please contact:

Novadip Biosciences

Jeff Abbey

Chief Executive Officer

+32 (10) 779 220

info@novadip.com

For media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Angela Gray

+44 (0) 20 3709 5700

novadip@consilium-comms.com

Read more from the original source:
Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science - GlobeNewswire

Dr Sister Ltd continues to offer effective skin treatments to both men and women, and they have been doing this for over 45 years now. Doctor Sister provides a comprehensive portfolio of treatments while at the same time delivering natural-looking, regenerative and enhancing results for the face and body. They are big believers in helping slow down the ageing process for each client, as of course, they are unable to stop time for you.

At Dr Sister Ltd, you can be treated by a professional doctor that trains other practitioners. Dr Sisterhimself has introduced over ten ground-breaking treatments to the UK market, along with eight published books, many articles in international peer reviews medical journals and general press, as well as being one of UKs and Europes leading lecturer and trainer in the field of Aesthetic Medicine.

The treatments offered by Dr Sister Ltd are non-invasive so there is no surgery and no downtime. Some of the skin treatments on offer at Dr Sister Ltd include the following; mini face lift, non-surgical face lift, vampire facial, PRP treatment and PRP injection. That is not an exhaustive list and he is also a renowned hormonal expert.

Dr. Sister has perfected safe, effective, natural-looking treatments, which has made him a worldwide expert and teacher in regenerative and innovative procedures such as Dracula PRP, Mint Lift including the new Stem Cell Facelift.

The PRP treatment (Dr. Sister has his own superior trademarked version called Dracula Therapy) may be unfamiliar to some clients. Dr Sister explains the procedure in great detail on their site. APRP treatment is a powerful anti-ageing treatment that involves using your blood as an injectable treatment (PRP Injection). Dr Daniel Sister was the first to introduce the treatment into the UK, and now he calls it Dracula Therapy.

With the Dracula Therapy or vampire facial, you will notice results within 3-4 weeks, and often only one PRP injection is required. However, the treatment may need to be repeated every 2-6 months because of the on-going ageing process.

The PRP injections generally appeal to patients looking for a more natural approach to facial rejuvenation, which is the rejuvenation process of using their cells. This treatment does not use synthetic fillers or animal products and has no risks or side effects.

At Dr Sister Ltd, they are well known for their aesthetic treatments, in particular, the MINT lift and Dr Sister is the training partner for the MINT lift. It is a PDO thread lift that offers exceptional results. Dr. Sister has been particularly impressed by the results as it provides an immediate and obvious lift, which many of his patients are looking for.

Dr Sister Ltd also mentions that local anaesthetic is used making the procedure pain free, and patients generally return to work and usual activities the following day. There are many benefits such as soft tissue lifting, instant lift, results lasting around 18 months.

If you would like to find out more about the treatments on offer at Dr Sister Ltd, there are many ways to get in touch. You can email press@drdanielsister.com your query, and they will get back to you as soon as possible, or you can go online to their website at https://drdanielsister.com. On their site, you will find all the information about the top treatments, fees, testimonials, and Dr Sister Ltd.

Source:https://thenewsfront.com/dr-sister-ltd-offers-effective-skin-treatments-to-both-men-and-women/

Link:
Dr Sister Ltd Offers Effective Skin Treatments to Both Men and Women - The News Front

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition. This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation. A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strong CAGR of 7.0% from 2018 to 2026. In 2017, the market was worth US$ 1,254.0 Mn and is expected to reach US$ 2,299.5 Mn by the end of the forecast period in 2026.

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

Read more here:
Induced Pluripotent Stem Cells Market To Register High Revenue Growthat 7% CAGR Throughout 2018 to 2026 - Kentucky Reports

TMRR, in its recent market report, suggests that the Stem Cell Therapy market report is set to exceed US$ xx Mn/Bn by 2029. The report finds that the Stem Cell Therapy market registered ~US$ xx Mn/Bn in 2018 and is spectated to grow at a healthy CAGR over the foreseeable period. This Stem Cell Therapy market study considers 2018 as the base year, 2019 as the estimated year, and 2019 2029 as the forecast timeframe.

The Stem Cell Therapy market research focuses on the market structure and various factors (positive and negative) affecting the growth of the market. The study encloses a precise evaluation of the Stem Cell Therapy market, including growth rate, current scenario, and volume inflation prospects, on the basis of DROT and Porters Five Forces analyses. In addition, the Stem Cell Therapy market study provides reliable and authentic projections regarding the technical jargon.

Important regions covered in the Stem Cell Therapy market research include Region 1 (Country 1, country 2), Region 2 (Country 1, country 2), Region 3 (Country 1, country 2) and Region 4 (Country 1, country 2).

Exclusive offer!!! Purchase reports at a discounted price!!!

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

The Stem Cell Therapy market study answers critical questions including:

The content of the Stem Cell Therapy market report includes the following insights:

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

On the basis of component, the global Stem Cell Therapy market report covers the following segments:

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

All the players running in the global Stem Cell Therapy market are elaborated thoroughly in the Stem Cell Therapy market report on the basis of R&D developments, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines, legal policies, and comparative analysis between the leading and emerging Stem Cell Therapy market players.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Why choose TMRR?

The rest is here:
Sales of the Stem Cell Therapy Market to Anticipated to Exceed US$ XX by 2017 - 2025 - Markets Gazette 24

Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2019 Industry Research Report gives vital information then analytical data of Autologous Stem Cell and Non-Stem Cell Based Therapies Market Size, Share, Growth, Key Players then forecast. Furthermore it provides development trends and marketing channels analysis. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. This report also presents product specification, manufacturing process, and product cost structure.

You can get a sample copy of this report at https://www.orianresearch.com/request-sample/1380754

Autologous stem-cell transplantation is autologous transplantation of stem cells in which stem cells are removed from an individual, stored, and later given back to that same individual.

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market was estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. The increase in chronic diseases is one of the chief factors supplementing the market growth. Conversely, the lack of awareness regarding the potential benefits of stem cells might hamper the market growth.

The global autologous stem cell and non-stem cell based therapies market is segmented on the basis of technology and region. Based on technology the market is segmented into neurodegenerative diseases, cardiovascular diseases, cancer and autoimmune diseases, skin transplantation and infectious disease. Based on region, it is studied across North America Europe, Asia-Pacific, South America and Middle East and Africa.

Inquire more or share questions if any before the purchase on this https://www.orianresearch.com/enquiry-before-buying/1380754 The key players profiled in the market include:* Antria* Bioheart* Brainstorm Cell Therapeutics* Cytori* Dendreon Corporation* Fibrocell* Genesis Biopharma* Georgia Health Sciences University* Neostem* Opexa Therapeutics

The report offers the market growth rate, size, and forecasts at the global level in addition as for the geographic areas: Latin America, Europe, Asia Pacific, North America, and Middle East & Africa. Also it analyses, roadways and provides the global market size of the main players in each region. Moreover, the report provides knowledge of the leading market players within the Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The industry changing factors for the market segments are explored in this report. This analysis report covers the growth factors of the worldwide market based on end-users.

Purchase Directly @ https://www.orianresearch.com/checkout/1380754

Key Benefits of the Report:

On the basis of technology, the market is split into:* Neurodegenerative Diseases* Cardiovascular Diseases* Cancer and Autoimmune Diseases* Skin Transplantation* Infectious Disease

Table of Contents:

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Market Research Report

1 Autologous Stem Cell and Non-Stem Cell Based Therapies Introduction and Market Overview

2 Industry Chain Analysis

3 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market, by Type

4 Autologous Stem Cell and Non-Stem Cell Based Therapies Market, by Application

5 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Production, Value ($) by Region (2014-2019)

6 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Production, Consumption, Export, Import by Regions (2014-2019)

7 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Status and SWOT Analysis by Regions

8 Competitive Landscape

9 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis and Forecast by Type and Application

10 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis and Forecast by Region

11 New Project Feasibility Analysis

12 Research Finding and Conclusion

13 Appendix

Customization Service of the Report:-

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us

Ruwin Mendez

President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727 | UK: +44 020 8144-71-27

Email: [emailprotected]

Website: http://www.orianresearch.com/

See the original post here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2019 by Technology (Neurodegenerative Diseases, Cardiovascular Diseases, Cancer and...

Within days of giving birth, a womans estrogen and progesterone levels quickly drop, leading to chemical changes in the brain that might give rise to shifts in mood. In fact, as many as three in four mothers experience symptoms of depression soon after childbirth. But for one in nine mothers, those symptoms result in a more serious, longer-lasting, and potentially life-threatening condition known as postpartum depression. The disorder, which manifests as a significant change in mood within hours to weeks of giving birth, is the most common complication of pregnancy. Currently, the depression drugs used to treat it take weeks to months to kick intime that new mothers (and their infants) cant afford. Zulresso is the first FDA-approved medication designed to tackle postpartum depression, and it does so at speed. The drug is a synthetic form of allopregnanolone, a hormone that dampens neural activity and eases depression symptoms when estrogen and progesterone levels dip. In double-blind control studies run by the creators at Sage Therapeutics, Zulresso worked within 60 hours. Right now, the drug is administered via a 60-hour intravenous infusion (common among new medicines), but alternative treatments, including a pill form, are currently in clinical trials.

Follow this link:
100 greatest innovations of 2019: Best of What's New - Popular Science

This is a guest contribution for The Economists Open Future initiative, which aims to foster a global conversation on the challenges of the 21st century. More Open Future articles are at Economist.com/openfuture

* * *

The day I knew I should quit my job answering phones at the transgender health-care clinic in California was the day a caller (lets use the name Betty) threatened her in-home caretaker with a knife during the call. As the caretaker begged our clinics nurse to track down Bettys doctor and tell him that Betty was having a psychotic episode, Betty stood between her and the apartments front door with a kitchen knife. Betty had poorly controlled paranoid schizophrenia, and often called the clinic agitated, alternately whispering and screaming about government agents stalking her. Betty was also a trans woman whom most people regarded as male, the sex of her birth.

Upgrade your inbox and get our Daily Dispatch and Editor's Picks.

The clinic followed the informed-consent protocol: its mission was to provide transgender patients who otherwise lacked access to health care with injections, skin patches and pills of feminising or masculinising hormones without having to pass through a series of requirements and assessmentsknown as gatekeepingthat restricted access in the past.

In medicine broadly, informed-consent refers to the ethical requirement that a clinician administering a treatment communicate to the patient the anticipated risks and benefits, as well as reasonable alternatives to the treatment. Yet for transition medicine in America, informed-consent programmes do not require clinical documentation, beyond patient reports, of the patients gender dysphoria over time (ie, a feeling of mismatch between ones biological sex and gender identity) and readiness for medical interventions.

Gatekeeping horror stories are notorious in the transgender community. In the past it was not unusual for a trans person to be told by doctors and psychologists they would not be referred for hormones because they were not visually appealing as their preferred gender, werent interested in dating the opposite gender, or had unresolved mental-health problems (some of which are predictable responses to experiencing transphobia, such as anxiety and depression).

It was not unusual for a trans person to be told they would not be referred for hormones because they were not visually appealing

Pioneering LGBT health centres across America developed informed-consent protocols for hormone treatment in a well-intentioned effort to imbue the experience of pursuing hormone treatment with dignity for patients. But as informed-consent protocols have become the norm rather than the exception, we may be shunting transgender people in America into a parallel medical systemone in which patients bargain away careful assessment and education for greater autonomy and shortened timelines to access medical treatments.

At my clinic, we were informed-consent true-believers. We didnt badger you with questions; as long as you were 18, even if you had no way to pay the clinics fees, you would get your hormones. You had to sign forms stating that you understood that although hormone-replacement therapy (HRT) benefits many trans people suffering from gender dysphoria, the health risks are largely unknown. Starting hormones could have negative consequences for your mental well-being, social functioning and even the intensity of your gender dysphoria (many people find that their distress about a body part like their breasts will only increase when the effects of testosterone appear, such as facial hair).

Also, people were informed that they were waiving the mental-health screening recommended by the World Professional Association for Transgender Health. Its standard of care recommends that patients seeking HRT be screened for schizotypal disorders, autism-spectrum disorders, personality disorders, dissociative disorders, post-traumatic stress disorders and more.

In the case of Betty, I felt that the clinic where I worked wasnt sufficiently concerned whether her mental disorder created delusions that often controlled her life, or meant she was so cognitively disabled that transition predictably left her more isolated and chronically stressed than before she started HRT. The medical staffs attitude towards Betty and many of the other patients who were receiving hormones while managing (or failing to manage) severe mental illness was a profound lack of interest about whether one affected the other.

We were informed-consent true-believers. We didnt badger you with questions; as long as you were 18, you would get your hormones.

In fact, most of us worked there because we rejected the idea that a strongly felt internal sense of gender could be a symptom of mental illness. That shared, ideological foundation meant it was verboten for the staff to consider whether the HRT might be exacerbating Bettys schizophrenic symptoms or making it harder for her to build the basic social relationships that provide the support and positive feedback that is so necessary for mental health. If the HRT did not actually assist Betty in presenting as a woman or improve her functioningand it seemed to be doing neitherwe considered affirming her identity more important than those conventional measures of the treatments effectiveness.

The most radical and liberatory action we could take was to affirm Bettys identity. If we were the one and only place she visited in her day where she was referred to using her chosen pronouns, we considered it paramount we gave her that experience. This commitment to affirming identity through correct pronouns and easy HRT was our reason for being. But strangely, by fulfilling our commitment to affirming felt identity, we seemed to be off the hook for questioning whether we were doing all we could to avoid harming her.

I quit the clinic in 2014, and in 2016 I spoke to the lawyer of a patient suing that same clinic. This patient also pursued HRT while experiencing intense delusional symptomsit was 2012 and he thought the world was ending. The clinic, affirming as ever, recommended and provided the referral letters for him to have an orchiectomy, a removal of his testicles, which he underwent. When his delusional symptoms eventually abated he detransitioned, coming to an uneasy peace being, and presenting as, male.

I know him because we are both detransitioned people. I was also convinced that I was a trans personas a result of misunderstanding a persistent sense that my body felt unreal, a common dissociative symptom following traumaand received HRT at this same clinic, taking testosterone for nine months. For the past five years Ive been a part of a growing community of detransitioned people who are speaking out about questionable norms and practices in transgender medicine.

The clinic, affirming as ever, provided the referral letters for him to have an orchiectomy, a removal of his testicles

When I first detransitioned, my community consisted of online groups of fewer than 100 women. Five years later the detransition discussion-forum on the popular site Reddit has just hit 7,000 people of both sexes. I know detransitioned people who later discovered they had autism-spectrum disorders, detransitioned people who came to recognise that they were experiencing traumatic dissociation, even detransitioned people who had such severe dissociation that they had multiple alters (ie, multiple identities) while being treated with hormones and surgeries.

Our stories, if taken seriously, could help improve the state of transgender health careparticularly at informed-consent clinics, which are becoming the norm at American colleges, LGBT health centres and recently many Planned Parenthoods. Instead we are ignored, compared to ex-gay Christians or treated as political footballs. (I was particularly disheartened when Ryan Anderson, a fellow at the Heritage Foundation, a conservative think-tank, used my and other detransitioners stories in his book that was critical of LGBT and feminist issues, When Harry Became Sally.)

That is because the burgeoning orthodoxy on the left is that detransition is so rare that only transphobes care about it. If you draw attention to the stories of transition gone wrong, the thinking goes, there will be less public support for transition and for transgender people themselves. For academic researchers and journalists, telling our stories is a fast track to being labelled a transphobe. This has profound consequences for what we know about the medical paths that leads to detransition.

In fact, we have no idea how prevalent detransition is in America. The most widely used estimate, that 2.2% of people who transition later detransition, comes from a study in a completely different place (Sweden) and time (1960-2010), when gatekeeping was much stricter. Moreover, that study defined a detransitioner as someone who had changed their name and gender legally (an arduous process in Sweden at the time) and then had the motivation and money to go through the name change process in reverse, a standard so strict that I wouldnt be counted, and nor would 90% of the detransitioners I know.

If you draw attention to the stories of transition gone wrong, the thinking goes, there will be less public support for transgender people

This passionate but misguided argumentthat detransition is extremely rare, thus any research into it is harmful and motivated by transphobiahas led to outright censorship. In 2017 Bath Spa University in Britain shot down a research proposal that sought simply to collect stories from detransitioners. The same year the Philadelphia Trans Health Conference, a major annual gathering of the transgender health community, abruptly cancelled two previously approved panels that I had helped organise on detransition and alternative methods of managing gender dysphoria, because of the level of heated conversation and controversy. These were just two out of nearly 200 sessions.

As a result, the subject of detransitioners health-care experiences remains virtually untouched by academic researchers. This shows in the clumsy approaches of those few researchers willing to engage the subject. For example, a poster presented this summer at the European Professional Association of Transgender Health conference purported to show a very low rate of detransition and regret (0.47%) at an NHS clinic in London. The poster bounced all over social media, cited as proof that detransition is indeed exceptionally rare.

But that estimate was generated by combing through case files for patients who returned to the clinic to inform staff of their detransition or regret. The thing is, though, detransitioners almost never do this. This is widely known within the communitywhy would you go back to a clinic or to a doctor who, in your view, helped you hurt yourself?

Apart from the few who sue their doctors and therapists, detransitioners tend simply to disappear from a clinics view, despite often having urgent needs for continued medical treatment and therapy. I have heard of only three detransitioners who went back to talk to the clinicians who had assisted them in transitioning. (The experience of one who did just that convinced me that I probably never will.) Nor do they tend to go to other clinics for follow-on care: they simply become invisible.

The majority of the studies supporting the conclusion that medical transition yields positive outcomesand there are manyfollowed patients in highly structured clinical programmes that provided comprehensive assessments. But when I searched last February for programmes that met that careful standard in America, I wasnt able to find one. No one knows whether informed-consent protocols will yield the same success rate, but the stories Ive heard during the past five years make me profoundly sceptical.

In a comprehensive examination of peer-reviewed articles on medical-transition between 1991 and 2017 by researchers art Cornell University, called What We Know, there have been no studies tracking a cohort of patients at an informed-consent clinic over time to investigate the outcomes that their protocol produces. Moreover, there have been no studies on what percentage of clinics in America follow the standard of care recommended by the World Professional Association for Transgender Health versus their own informed-consent protocols.

From the point of view of clinics, they would respond to the criticisms by noting that informed-consent clinics often serve a poor and transient population, which presents challenges to following up with patients. Another difficulty is that transgender medicine is a relatively new field serving a small minority of the population, necessarily limiting funding and opportunities for research. As to whether informed-consent policies have the effect of leading people to medical interventions too soon, they would argue that the people who end up feeling ill-served by the high level of patient autonomy will always be a small minority.

Yet this does not obviate the need for better practices. I dont want informed-consent clinics shuttered. I want them to do the tasks normally associated with medical care. This includes giving patients access to differential diagnosis (distinguishing between conditions that share similar symptoms) and follow-up research so that providers can improve the care they offer.

There is a responsible path between making transgender people jump through hoops and allowing people experiencing psychosis to have their testicles removed

For example, ensuring that low-cost psychology referrals are offered to all patients seeking informed-consent care could increase voluntary participation in comprehensive evaluations. Ensuring that staff are trained to identify patients showing signs of certain severe disorders, and to provide psychological evaluations when appropriate, could help prevent outcomes like Bettys.

Even ensuring that all clinics have counselling referrals on hand would be a step in the right direction. Although I received a prescription for hormones by my second visit, many patients sat on the waiting list for counselling from the same clinics social workers for more than five months and when I requested an outside referral, I was told to google the phone number of a local counselling internship site.

There is a responsible middle path between making transgender people jump through hoops to access needed medical care and allowing people experiencing psychosis and delusions to have their testicles removed. Until gender care providers accept their ethical responsibility to find that path, the American medical system continues to serve this community of people poorlybut this time, this neglect is designed and perpetrated by allies under the banner of transgender rights.

_________________

Carey Callahan is a family therapist and board member of the Gender Care Consumer Advocacy Network, a non-profit group that advocates for the rights and welfare of consumers of gender care services.

Go here to read the rest:
Gender identity is hard but jumping to medical solutions is worse - The Economist

Mitchell Levine is the new director of the Dental Sleep Medicine Clinic at the University of Tennessee Health Science Center's College of Dentistry.(Photo: Natalie Brewer / UTHSC)

Mitchell Levine wants the clinic he leads to help Shelby County Schools "educate and inform" faculty on identifyingchildren with sleep apnea, which can hinder brain development.

I think faculty in particular may just not be aware, said Levine, director of the Dental Sleep Medicine Clinic at the University of Tennessee Health Science Centers College of Dentistry. They think the child is just not performing well or acting out. They dont always associate it with sleep problems.

Sleep apnea isa condition in which the airway is blocked during sleep, obstructing oxygen intake. It can increase the risk of heart disease and other disorders, according to the National Heart, Lung,and Blood Institute.

For adults, using continuous positive air pressure (CPAP) machines manages the problem. Getting children desensitized and willing to use a CPAP is "no doubt" more difficult, Levine said, and untreated sleep apnea can hinder their neurological, psychosocial and decision-making development, according to UTHSC.

Dental assistant Abby Ridings (left) and fourth-year dental student Carlton Leding clean 11-year-old Tierra Moore's teeth during a visit to the University of Tennessee Health Science Center College of Dentistry on National Give Kids A Smile Day on Thursday, Feb. 2, 2017.(Photo: Yalonda M. James/USA TODAY NETWORK - Tennessee)

That manifests itself in shortcomings at school, which could spiral into challenges beyond the classroom, said Levine, who became director Aug. 1.

Kids who are not being managed well (with sleep breathing) puts them at a disadvantage as they continue to age, he said.

Tackling adult sleep apnea is about managing the problem, unless there is a willingness to undergo major surgery, Levine said. CPAP or oral devices that fit like retainers and keep the airway openare typical treatment options, per UTHSC.

For pediatric sleep apnea, Levine said treating it isabout redirecting the growth processes of the jaw to improve the effectiveness of the airway during sleep.Jaw positioning and enlarged tonsils and adenoids are connected to sleep apnea in children, Levine said.

When snoring becomes a regular occurrence it could be a more serious condition called obstructive sleep apnea. Many use a CPAP mask to help get past this condition.(Photo: nicolesy, Getty Images/iStockphoto)

I think what were realizing is in childrens sleep problems and adults' sleep problems is the manifestations of them seem to be a bit different, he said.

Repositioning the jaw is effective when the child is 8 or 9 years old and growing fast. Before that age range, oral devices come in handy, because structural changes to growth aren't as effective at 5 or 6 years old, Levine said.

An oral device may be all that's needed for a young child with sleep apnea. Over time, natural growth may rid the child of the structural cause, Levine said.

We had parents that would talk about kids not having nightmares anymore or sleepwalking, doing better at school and moving into their own bedrooms again, Levine said of helping children with sleep apnea. There is a unique opportunity on the pediatric side.

Levine hopes UTHSC and the clinic he heads willfind a role in the community beyond custom-fitted oral devices and orthodontic treatments.

Addressing children with sleep-breathing problemsis a key example of that, being a new focus for the clinic. Levine said he has a different perspective than previous leadership due to his experience treating children and addressing orthodontic development.

A dental implant designed by Dr. Ryan Robinson, a dentist at Pike Creek Dental, to treat patients diagnosed with sleep apnea.(Photo: Jennifer Corbett, The News Journal)

If Shelby County Schools faculty can identify children with pediatric sleep apnea, they can direct them to resources that will address the disease, Levine said. SCS and UTHSC have a general partnership already, but a more direct, sleep apnea-focused effort would boost awareness regarding the issue.

Other factors can negatively affect sleep for young people outside of trouble breathing, like using electronics before bed, Levine pointed out. Blue light emitted from smartphones, tablets and other devices competes with melatonin, a natural hormone connected to the onset of sleep.

Early school start times are also a big issue, particularly among high school students with delayed sleep patterns, homework and after-school activities to manage, Levine said. Those students can be at risk for drowsy driving.

A whole education process needs to be introduced, he said.

Max Garland covers FedEx, logistics and health care for The Commercial Appeal. Reach him at max.garland@commercialappeal.com or 901-529-2651 and on Twitter @MaxGarlandTypes.

Read or Share this story: https://www.commercialappeal.com/story/news/2019/12/03/child-sleep-apnea-uthsc-dental-sleep-medicine-clinic-mitchell-levine/4299784002/

See the rest here:
Child sleep apnea: Here's why UTHSC clinic director wants to team up with Shelby County Schools - Commercial Appeal

with Ali Aminian, MD, and Caroline Apovian, MD

For those of you who have type 2 diabetes with obesity or have a family member that does, one of the best ways to reduce common health risks such as heart disease and stroke is by having gastric bypass surgery.1

The reason for this seems to be that metabolic surgeryany procedure that changes the function and structure of the stomach or small intestinesupports weight loss, leading to improvements in glucose control and insulin sensitivity; and, ultimately diminishes the complications associated with diabetes. Still, how can you be sure that surgery is the right way to go?

Cleveland Clinic researchers have developed a risk assessment tool to give you a sense of your health risks for diabetes complications in the decade ahead if you do or don't have bariatric surgery. Photo: fstop123 @ iStock

Recognizing that surgery is a daunting step for some and represents too much uncertainty for others, a web-based risk assessment calculator was created by a team of investigators at the Cleveland Clinic in Ohio to help you to determine if bariatric surgery will favorably improve your long-term health.2,3 The results can be shared with your health provider as a starting off point in discussing a disease management plan now and going forward.

This predictive tool is intended to guide you and your doctor to understand the long-term medical risks associated with type 2 diabetes (T2D) and obesity, and to consider the benefits you might gain from having this surgery,2 says Ali Aminian, MD, a bariatric surgeon at the Cleveland Clinic who presented the research supporting development of this tool at a session during ObesityWeek 2019, in Las Vegas, Nevada.

Dr. Aminian outlined the development of the risk calculator. He and his team evaluated the experiences of 13,722 patients with both diabetes and obesitycomparing patients who underwent bariatric surgery as compared to closely matched individuals who were eligible for surgery but chose to continue with their standard medical treatment.2

After following these patients, the individuals who elected to have surgery proved to have a lower risk for every one of the five common complications associated with diabetes. These included: heart disease, stroke, heart failure, kidney disease, and death from all causes.2

Across the board, following these gastric procedures, individuals had a lower risk of every diabetes-related risk. Unfortunately, fewer than 1% of the patients who were eligible for bariatric surgery have it,3 he says.

The researchers than gathered relevant data from the medical records of nearly 290,000 patients with obesity who were being treated for type 2 diabetes in the Cleveland Clinic Health System from 2004 to 2007.Health measures including age, sex, body mass index (BMI), diabetes-related complications, and medications taken were combined to determine patient-specific risks. The researchers also incorporated levels of hemoglobin A1c, blood pressure, and blood cholesterol levels.3

The data supporting the impact of weight-loss surgery on complications of type 2 diabetes, such as stroke and heart disease as well as kidney disease, was published in the Journal of the American Medical Association.2 The results support use of the risk calculator since the data indicated that patients who had metabolic surgery were 39% less likely to experience conditions such as heart disease, stroke, or diabetic kidney disease and 41% were less likely to die from any cause.2,3

When used by an individual, the risk assessment tool can help give both patients and providers a 10-year disease probability of developing the life-threatening complications related to diabetes if the current path is continued, as well as a comparison should you choose to undergo bariatric surgery.

How Effective Is the Gastric Bypass Risk Assessment Tool? As the Individualized Diabetes Complications (IDC) risk calculator was only just released, there hadnt been enough time to gather feedback yet, Dr. Aminian tells EndocrineWeb. However, he has already heard from several enodcrinologists, cardiologists, and primary care providers that they intend to use the calculator in their practices.

According to Caroline Apovian, MD, of Boston University School of Medicine, the reason for greater disease complications stems from a failure of primary care physicians and endocrinologists to recommend more eligible patients discuss their status with a bariatric surgeon. This risk calculator will help not just patients but also providers to realize the benefits of gastric surgery beyond weight loss, and to recognize the risks of not choosing to have surgery, she says.

While there isnt currently a way to determine which bariatric procedure would be best for each individual, Dr. Apovian tells EndocrineWeb, there are studies that indicate that the Roux-en-Y Gastric Bypass offers the best effect on hormone levels.4-6Dr. Aminian acknowledges that despite the limitations of the risk assessment tool as it doesnt include information on family history of heart disease or length of time with type 2 diabeteswhich would be helpful in addressing patient risk, the results derived by the IDC assessment are still valid.2,3

These gastric procedures are very powerful and safe methods for treating individuals with both obesity and type 2 diabetes, says Dr. Aminian. Having surgery can provide significant weight loss, improve diabetes, cholesterol levels, delivering a survival benefit as well as improved quality of life. Even though treating these patients with bariatric surgery is known to be beneficial, a lack of access to trained surgeons and the stigma associated with any method of weight loss besides diet and exercise, has made this option less desirable, he says.

Dr. Apovian has already made use of the ICD assessment tool in her practice It adds a spotlight that can help patients to better grasp the benefits to surgery.

In another presentation delivered at ObesityWeek 2019 in Las Vegas, Nevada, Oliver Varban, MD, associate professor of surgery including bariatric procedures in the University of Michigan Health System in Ann Arbor, presented data supporting the value of sleeve gastrectomy for individuals who have mild obesity (ie, body mass index [BMI] < 35 kg/m2).7 In this study of more than 45,000 patients, achieving a normal BMI occurring more often in patients with a starting BMI below 35 than above who also voiced greater satisfaction with the procedure.

In a press statement, Dr. Varban said: We hope the study encourages more patients to consider weight loss surgery earlier in their disease and for more health insurers to recognize the benefits of lowering the current BMI-threshold.

Indeed, it is most constructive for providers to introduce patients to this surgical assessment tool to help illuminate the risks individuals likely face in avoiding bariatric surgery, says Dr. Apovian. She anticipates that providers and patients might use the ICD tool together in an office setting when considering the need for treatment to improve outcomes and better manage type 2 diabetes with obesity.

Both physicians and patients still fail to treat obesity as a disease, says Dr. Apovian, raising a long-held observation. Too many doctors still view obesity as a matter of willpower and self-control, expecting patients alone to carry full responsiblity for losing weight. There is need for the medical community to acknowledge that obesity is a malfunction of metabolic pathways driving hunger and satiety talk between the gut and the brain.

Any educational tool that offers to dispel this old way of thinking is very welcome, says Dr. Apovian, as we need to help change attitudes so obesity can be approached as disease in need of medical intervention.

In the future, having more information included in the tool on who will develop heart disease on a genetic level could help patients and providers better target particular treatments to specific people.

The assessment algorithm doesnt allow for influences that may change the results based on demographic information such as race and ethnicity.2 Dr. Apovian has studied the impacts of surgery on different populations, and recently published data that showed that African American and Latino populations dont respond as well as Caucasians to metabolic surgery and are more likely to relapse into diabetes.4

Knowing the reasons for variability in outcomes based on racial differences could assure a more accurate and wider use of the ICD assessment tool but such developments still need more time in the academic incubator.2

More data on the type of surgery and outcomes across subpopulations would be good, says Dr. Apovian, particularly as sleeve gastrectomy produces a different impact on hormones related to satiety then the Roux-en-Y gastric procedure. We are starting to see conversions to Roux-en-Y after failed sleeve surgeries, she says.

As for the ICD tool, Id love to see all practitioners using this in their practices, says Dr. Apovian. It introduces sound numbers to the conversation with patients, and if that helps doctors convert more patients to opt in to surgery, then that will be great.

The Cleveland Clinic research received a research grant from Medtronic.

Last updated on 12/03/2019

Big Breakfast Beats Traditional 6-Meal Diabetes Diet

Continue reading here:
Web-based Tool to Help Assess Diabetes Outcomes With and Without Surgery - EndocrineWeb